Media Mention

Bryant Godfrey Discusses Drug Ads on Social Media with Bloomberg Law

December 15, 2023

Foley Hoag Partner and FDA Practice Co-chair Bryant Godfrey provides insight in a recent Bloomberg Law article discussing how drug ads on social media platforms that go unchecked by the FDA are putting consumers at risk. 

While social media ads are required to follow the same guidelines as conventional ad forms, Bloomberg found such ads provide limited-to-no product warnings. FDA’s drafted its social media guidance in 2014, which was never finalized. Godfrey noted that “FDA officials knew when they were drafting the policies in 2014 that social media would evolve” and added that “there’s so many different social media channels out there that FDA clearly didn’t have an idea of what would be down the line.” As FDA’s social media ad regulation continues to evolve with the help of OPDP research, “FDA could establish an online form or another formalized intake measure for submitting complaints to its Bad Ad Program.” He continues stating “If there was something more in place, such as an online reporting mechanism, the agency would be able to better see trends and kind of get ahead of it, even from a policy standpoint.”

Read the full article here.